NEW YORK (GenomeWeb News) — Asuragen Pharmacogenomic Services, a division of Asuragen, will develop a biomarker and pharmacogenomic test for a Merck cancer program, Asuragen said today.
 
Terms of the deal call for Asuragen to apply information from an expression signature identified by Merck's oncology research program to develop a diagnostic assay for use in Merck's cancer clinical trials, and to “potentially form the basis for commercial companion diagnostic tests for oncology therapies.”
 

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.